Please wait while we load the requested 10-Q report or click the link below:
Revenue of $461.6 million, up 0.5% from the prior-year period and 5.1% on a constant currency basis
Revenue from Advanced Wound Therapeutics (“AWT”) devices grew double digits in the U.S. led by double digit volume increases compared to the prior-year period
Loss from continuing operations improved to $17.6 million compared to $153.8 million in the prior-year period
Adjusted EBITDA from continuing operations1 of $172.9 million, grew 2.9% versus the prior-year period and 5.6% on a constant currency basis, achieving an Adjusted EBITDA margin of 37.5%
Acelity’s revolutionary V.A.C.® Therapy technology achieves another record level of seasonally adjusted worldwide rental volumes
Announced two innovative product offerings in Europe: TIELLE® Non Adhesive, intended to manage a range of exudate levels and increase the comfort and ease for a patient; and the REVOLVE™ System which offers fast, efficient and secure fat tissue processing in a range of reconstructive procedures
The following information was filed by Acelity L.P. Inc. on Wednesday, July 29, 2015 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.
View differences made from one quarter to another to evaluate Acelity L.P. Inc.'s financial trajectory
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were
removed , and by Acelity L.P. Inc..